Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: CTEP LOI# 9231 - A phase I trial of dinaciclib (SCH727965) and MK-2206 in metastatic pancreatic cancer with an expansion cohort in advanced pancreatic cancer

 


CTEP LOI# 9231 - A phase I trial of dinaciclib (SCH727965) and MK-2206 in metastatic pancreatic cancer with an expansion cohort in advanced pancreatic cancer


Trial Focus

Digestive System Cancer

Objective

         This is a clinical trial of investigational drugs Dinaciclib that will be administered intravenously and MK2206 that will be administered by orally

IRB Protocol #

13-1969

Trial Status

OPEN

Principle Investigator

COLIN WEEKES

Sponsor

UCCC

Contact

HALEY CHILES at (720)848-5097 or HALEY.CHILES@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period to determine eligibility. Treatment period will vary. A follow up period will consist of periodic phone calls or emails. // Eligibility criteria include but are not limited to 18 years or older with Metastatic Pancreatic Cancer with an Expansion Cohort in Advanced Pancreatic Cancer Eligibility criteria include but are not limited to 18 years or older with Metastatic Pancreatic Cancer with an Expansion Cohort in Advanced Pancreatic Cancer